Should Journal Editors Play Science Cops?

The two principal Charles Bluestone and Erdem Cantekin, key members of a group, that began a major clinical trial in 1981 to measure the efficacy of drugs used to treat diseases in the middle ear in children. Bluestone, an otolaryngologist, is director of the Otitis Media Research Center and principal investigator on the $5.6 million NIH grant that supported the work at Children's Hospital. Cantekin, a biomedical engineer was the center's director of research. Cantekin, whose paper remains unp

The Scientist Staff
Oct 30, 1988

The two principal Charles Bluestone and Erdem Cantekin, key members of a group, that began a major clinical trial in 1981 to measure the efficacy of drugs used to treat diseases in the middle ear in children. Bluestone, an otolaryngologist, is director of the Otitis Media Research Center and principal investigator on the $5.6 million NIH grant that supported the work at Children's Hospital. Cantekin, a biomedical engineer was the center's director of research.

Cantekin, whose paper remains unpublished, told a congressional panel September 27 that research at the center is being distorted by the fact that the center recieves funding from several drug companies. He added that certain find- ings made by the research team are seriously flawed. His analysis of the same data attempts to show that the drugs tested are no more effective in clearirg up the disease than is no treatment at all. A University of...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?